• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Alimera Sciences Inc. (Amendment)

    2/13/24 4:24:52 PM ET
    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALIM alert in real time by email
    SC 13G/A 1 alim13ga.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

     

    Alimera Sciences, Inc.

    (Name of Issuer)

     

     

    Common Stock, $0.01 par value per share

    (Title of Class of Securities)

     

     

    016259202

    (CUSIP Number)

     

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 
    CUSIP No. 016259202

     

    1.Names of Reporting Persons.

    Stonepine Capital Management, LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization California

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 5,373,732

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 5,373,732

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 5,373,732

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.99%

     

    12.Type of Reporting Person (See Instructions) IA, OO

     

     2 
    CUSIP No. 016259202

     

    1.Names of Reporting Persons.

    Stonepine Capital, L.P.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 5,373,732

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 5,373,732

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 5,373,732

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.99%

     

    12.Type of Reporting Person (See Instructions) PN

     

     3 
    CUSIP No. 016259202

    Names of Reporting Persons.

    Jon M. Plexico

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 5,373,732

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 5,373,732

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 5,373,732

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.99%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     

     4 
    CUSIP No. 016259202

    Names of Reporting Persons.

    Timothy P. Lynch

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 5,373,732

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 5,373,732

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 5,373,732

     

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.99%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     

     5 
    CUSIP No. 016259202

    Item 1.

     

    (a)Name of Issuer

    Alimera Sciences, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

    6310 Town Square, Suite 400, Alpharetta, GA 30005

     

     

    Item 2.

     

    (a)The names of the persons filing this statement are:


    Stonepine Capital Management, LLC, a California limited liability company (the “General Partner”)

     

    Stonepine Capital, L.P., a Delaware limited partnership (the “Partnership”)

     

    Jon M. Plexico

     

    Timothy P. Lynch (collectively, the “Filers”)

     

    The General Partner is the general partner and investment adviser of investment funds, including the Partnership. Mr. Plexico and Mr. Lynch are the control persons of the General Partner. The Filers are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    (b)The principal business office of the Filers is located at

     

    919 NW Bond Street, Suite 204

    Bend, OR 97703

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Common Stock, $0.01 par value per share (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: 016259202
     6 
    CUSIP No. 016259202
    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[X] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E). As to the General Partner.

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[X] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G). As to Mr. Plexico and Mr. Lynch.

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page for each Filer.

     

    The shares of the Stock beneficially owned by the Filers reported in this Schedule 13G consist of (1) 3,999,459 shares of the Stock, and (2) Prefunded Warrants to acquire 2,000,000 shares of the Stock, which Prefunded Warrants are subject to a 9.99% beneficial ownership limitation. The percentages reported in this Schedule 13G are based on 52,416,841 shares of the Stock outstanding as of October 27, 2023 as reported in the Form 10-Q filed by the Issuer on November 2, 2023.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    The Partnership holds the Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.


    Item 10.
    Material to Be Filed as Exhibits

    Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G.

    Item 11.Certification of the General Partner, Mr. Plexico and Mr. Lynch

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of the Partnership

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     7 
    CUSIP No. 016259202

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 13, 2024

     

     

    STONEPINE CAPITAL MANAGEMENT, LLC


    By: /s/ Timothy P. Lynch
    Timothy P. Lynch
    Managing Member

     

     

    STONEPINE CAPITAL, L.P.

    By: Stonepine Capital Management, LLC,
    General Partner

    By: /s/ Timothy P. Lynch
    Timothy P. Lynch
    Managing Member

     

     

     

    /s/ Jon M. Plexico

    Jon M. Plexico

     

     

    /s/ Timothy P. Lynch

    Timothy P. Lynch

     

     8 
    CUSIP No. 016259202

    EXHIBIT A

     

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Stonepine Capital Management, LLC, a California limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

    Dated: May 15, 2017

     

     

    STONEPINE CAPITAL MANAGEMENT, LLC


    By: /s/ Timothy P. Lynch
    Managing Member

     

     

    STONEPINE CAPITAL, L.P.

    By: Stonepine Capital Management, LLC,
    General Partner

    By: /s/ Timothy P. Lynch
    Managing Member

     

     
    /s/ Jon M. Plexico
     

     


    /s/ Timothy P. Lynch

     

     

    Get the next $ALIM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALIM

    DatePrice TargetRatingAnalyst
    6/25/2024Buy → Neutral
    H.C. Wainwright
    3/25/2024$10.00Buy
    Maxim Group
    10/30/2023$8.00Neutral → Buy
    Alliance Global Partners
    2/25/2022$12.00 → $10.00Buy
    HC Wainwright & Co.
    8/16/2021$16.00 → $12.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ALIM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences

      Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a pro forma basisAdds two durable commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI's foothold in strategic therapeutic area of ophthalmologyAnticipated to drive high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafterNew capital structure in place, reducing interest expense by approximately $39 million on an annualized basis (1)ANI maintains its 2024 financial guidance for the standalone Company based on continued momentum across Purified Cortrophin® Gel (Cortrophin

      9/16/24 8:53:27 AM ET
      $ALIM
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences

      PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") announced today that the Company has initiated closing logistics for the previously announced acquisition of Alimera Sciences, Inc. (NASDAQ:ALIM). The Company expects closing of the acquisition of Alimera Sciences to be consummated and announced today, pending satisfaction or waiver of any remaining customary closing conditions. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical pr

      9/16/24 6:50:00 AM ET
      $ALIM
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger

      PRINCETON, N.J. and ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI") and Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company") today jointly announced that they have scheduled the closing of their transaction pursuant to the companies' previously announced Merger Agreement for before the market opens on Monday, September 16, 2024. About ANI Pharmaceuticals, Inc.ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medic

      9/11/24 6:50:00 AM ET
      $ALIM
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALIM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Maltz Elliot

      4 - ALIMERA SCIENCES INC (0001267602) (Issuer)

      9/18/24 9:54:11 PM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kaseta Michael

      4 - ALIMERA SCIENCES INC (0001267602) (Issuer)

      9/18/24 9:53:50 PM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Marketing Officer & SVP Holland David returned 187,756 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - ALIMERA SCIENCES INC (0001267602) (Issuer)

      9/18/24 9:53:32 PM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALIM
    Leadership Updates

    Live Leadership Updates

    See more
    • Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced the appointment of Todd Wood as President U.S. effective immediately.  "As we prepare to enter 2024 with a significantly larger U.S. business, we are excited to have Todd join our team to oversee our U.S. operations and accelerate our growth trajectory," said Rick Eiswirth, Alimera's President and CEO. "Todd brings strong commercial leadership across sales, marketing and market access from b

      12/12/23 7:30:00 AM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alimera Appoints Maggie A. Pax to Its Board of Directors

      ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Maggie A. Pax to its Board of Directors. Ms. Pax presently serves on the board of several life sciences companies. "Maggie's experience within growing companies, leading product development, business strategy, supply chain, and commercial teams, along with leading the development of business partnerships, will bring additional operational experience to our board," said Rick Eiswirth, Alimera's Pr

      11/8/23 4:30:00 PM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alimera Sciences Appoints Jason Werner as Chief Operating Officer

      ATLANTA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced the appointment of Jason Werner, Chief Operating Officer ("COO"), effective October 2, 2023. In conjunction with this appointment, Dr. Philip Ashman, previously Alimera's Chief Operating Officer and Senior Vice President, Commercial Operations Europe, was appointed President of International Operations. "Jason has been a strong voice and insightful influence on our board since joining earlier this year, and we

      10/3/23 8:00:00 AM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALIM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alimera Sciences downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Alimera Sciences from Buy to Neutral

      6/25/24 7:18:10 AM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Alimera Sciences with a new price target

      Maxim Group initiated coverage of Alimera Sciences with a rating of Buy and set a new price target of $10.00

      3/25/24 7:50:48 AM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alimera Sciences upgraded by Alliance Global Partners with a new price target

      Alliance Global Partners upgraded Alimera Sciences from Neutral to Buy and set a new price target of $8.00

      10/30/23 11:06:19 AM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALIM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Alimera Sciences Inc.

      SC 13D/A - ALIMERA SCIENCES INC (0001267602) (Subject)

      9/18/24 4:30:11 PM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Alimera Sciences Inc.

      SC 13D/A - ALIMERA SCIENCES INC (0001267602) (Subject)

      9/16/24 5:10:24 PM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Alimera Sciences Inc.

      SC 13D/A - ALIMERA SCIENCES INC (0001267602) (Subject)

      6/24/24 7:30:16 PM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALIM
    Financials

    Live finance-specific insights

    See more
    • Alimera Sciences Reports Second Quarter 2024 Results

      Net Revenue up 54% to $27 Million vs. Q2 2023Global End User Demand up 6% vs. Q2 2023Company Recently Announced Definitive Merger Agreement with ANI Pharmaceuticals, Inc. ATLANTA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2024. Alimera will not host a conference call today due to the recently announced agreement to be acquired by ANI Pharmaceuticals, Inc. ("ANI"). "We are plea

      8/6/24 7:30:00 AM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences

      Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenueAdds two commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI's foothold in key strategic therapeutic area of ophthalmology Anticipated to drive high single digit to low double digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafterExpected to generate additional $35 - $38 million in 2025 adjusted non-GAAP EBITDA inclusive of approximately $10 million in identified cost synergies; additional EBITDA contribution expected from a

      6/24/24 6:50:44 AM ET
      $ALIM
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alimera Sciences Reports First Quarter 2024 Results

      Net Revenue up 70% to $23 Million vs. Q1 2023Global End User Demand Up 23% vs. Q1 2023Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2024. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results. "Our results in this quarter were consistent with our expectations as we continue to integrate YUTIQ into our U.S. business and sup

      5/14/24 7:30:00 AM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALIM
    SEC Filings

    See more
    • SEC Form 15-12G filed by Alimera Sciences Inc.

      15-12G - ALIMERA SCIENCES INC (0001267602) (Filer)

      9/26/24 4:55:34 PM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Alimera Sciences Inc.

      EFFECT - ALIMERA SCIENCES INC (0001267602) (Filer)

      9/23/24 12:15:05 AM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Alimera Sciences Inc.

      EFFECT - ALIMERA SCIENCES INC (0001267602) (Filer)

      9/23/24 12:15:02 AM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care